Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Shigellosis | 0 | map05131 | albendazole | 6604200 | drug-path |
Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | albendazole | 6604200 | drug-path |
Amyotrophic lateral sclerosis (ALS) | Q8NDH6-2 | 0 | albendazole | 6604200 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | albendazole | 6604200 | drug-path |
Apoptosis | R-HSA-109581 | map04210 | albendazole | 6604200 | drug-path |
Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | albendazole | 6604200 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | labetalol | 3869 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | labetalol | 3869 | drug-path |
Circadian rhythm - mammal | R-HSA-400253 | 0 | labetalol | 3869 | drug-path |
Cell cycle | R-HSA-1640170 | map04110 | labetalol | 3869 | drug-path |
ECM-receptor interaction | R-HSA-373711 | map04512 | labetalol | 3869 | drug-path |
Chemokine signaling pathway | R-HSA-168638 | map04062 | labetalol | 3869 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | labetalol | 3869 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | labetalol | 3869 | drug-path |
Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | labetalol | 3869 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | labetalol | 3869 | drug-path |
Gap junction | R-HSA-190861 | map04540 | labetalol | 3869 | drug-path |
Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | labetalol | 3869 | drug-path |
Ribosome | R-HSA-5368277 | map03010 | labetalol | 3869 | drug-path |
Alzheimer's disease | R-HSA-1643685 | 0 | oxybutynin | 4634 | drug-path |